News from the FDA/CDC
News
FDA warns of potentially lethal reaction to seizure meds
Diagnosis is often difficult because early signs and symptoms, such as fever and swollen lymph nodes, may be present without evidence of a rash....
News from the FDA/CDC
New at-home test approved for chlamydia and gonorrhea
“This authorization marks an important public health milestone, giving patients more information about their health from the privacy of their own...
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
News from the FDA/CDC
FDA approves abatacept for pediatric patients with psoriatic arthritis
As many as 5% of pediatric patients with juvenile idiopathic arthritis are estimated to have juvenile PsA.
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...
Latest News
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
The cosmetic products include makeup products, nail polishes, shaving creams, other grooming products, perfumes, face and body cleansers, hair...
Latest News
Despite recent uptick in cases, leprosy is very rare, expert says
Over the past several years, 150-250 cases of leprosy have been reported each year.
News from the FDA/CDC
Pneumococcal vaccine label adds injection-site risk
Reports of injection-site necrosis emerged after the vaccine had been approved by the FDA and was administered to a large, diverse, real-world...
News from the FDA/CDC
FDA approves first over-the-counter birth control pill
The product, OPill, is expected to be available early in 2024.
News from the FDA/CDC
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...